Results 191 to 200 of about 14,917 (240)
Some of the next articles are maybe not open access.
Therapeutic Targets in Myelodysplastic Neoplasms: Beyond Hypomethylating Agents
Current Hematologic Malignancy Reports, 2023To discuss novel targeted therapies under investigation for treatment of myelodysplastic neoplasms (MDS).Over the last few years, results of phase 3 trials assessing novel therapies for high-risk MDS have been largely disappointing. Pevonedistat (NEDD-8 inhibitor) and APR-246 (TP53 reactivator) both did not meet trial endpoints.
Prateek Pophali +2 more
openaire +2 more sources
Hypomethylating Agents for Urologic Cancers
Future Oncology, 2011Silencing of tumor suppressor genes by promoter-region methylation as an epigenetic mechanism of gene regulation is increasingly recognized as beneficial in cancer. Initially developed as cytotoxic high-dose therapies, azacitidine and decitabine are now being reinvestigated in lower-dose cancer treatment regimens with a different paradigm ...
Ajjai S, Alva +5 more
openaire +2 more sources
Hypomethylating agents and chemotherapy in MDS
Best Practice & Research Clinical Haematology, 2013Until recently, the treatment of higher risk myelodysplastic syndrome was based on [1] Intensive chemotherapy using anthracycline-AraC combinations, leading to a lower complete remission rates and a shorter CR duration compared with de novo AML [2], low dose chemotherapy with limited CR rate mainly restricted to patients with normal karyotype ...
Adès, Lionel, SANTINI, VALERIA
openaire +3 more sources
Optimizing hypomethylating agents in myelodysplastic syndromes
Current Opinion in Hematology, 2012Hypomethylating agents (HMAs) improve the outcome of higher-risk myelodysplastic syndromes (MDS) and provide multilineage response in lower-risk patients but their results must be optimized, especially as the poor outcome of patients after HMA failure is now established.Current efforts include evaluation of novel outpatient administration schedules and
Raphael, Itzykson, Pierre, Fenaux
openaire +2 more sources
Curcumin is a potent DNA hypomethylation agent
Bioorganic & Medicinal Chemistry Letters, 2009Molecular docking of the interaction of curcumin and DNMT1 suggested that curcumin covalently blocks the catalytic thiolate of C1226 of DNMT1 to exert its inhibitory effect. This was validated by showing that curcumin inhibits the activity of M. SssI with an IC(50) of 30 nM, but no inhibitory activity of hexahydrocurcumin up to 100 microM. In addition,
Zhongfa, Liu +11 more
openaire +2 more sources
Leveraging Hypomethylating Agents for Better MDS Therapy
Current Hematologic Malignancy Reports, 2018Myelodysplastic syndrome (MDS) is a clinically and molecularly heterogeneous disease, which primarily occurs in older adults. Although hypomethylating agents have survival benefit and are the current standard of care, many MDS patients will not garner a response from therapy.
Terrence J, Bradley +2 more
openaire +2 more sources
Hypomethylating Agents as a Therapy for AML
Current Hematologic Malignancy Reports, 2017Acute myeloid leukemia (AML) is predominantly a disease of older adults associated with poor long-term outcomes with available therapies. Used as single agents, hypomethylating agents (HMAs) induce only 15 to 25% complete remissions, but current data suggest that median OS observed after HMAs is comparable to that observed after more intensive ...
Claude, Gardin, Hervé, Dombret
openaire +2 more sources
Clinical Advances in Hypomethylating Agents Targeting Epigenetic Pathways
Current Cancer Drug Targets, 2010DNA methylation and histone acetylation are two most studied epigenetic markers. Aberrant methylation of gene promoter regions and histone tail lysine residue modification through acetylation and methylation play a key role in malignant disorders. Two DNA methyltransferase inhibitors, azacitidine and decitabine, have been licensed for clinical therapy ...
S, Cang, Q, Lu, Y, Ma, D, Liu
openaire +2 more sources
Novel approaches for myelodysplastic syndromes: beyond hypomethylating agents
Current Opinion in Hematology, 2010Several novel therapeutic approaches exist for treatment of patients with myelodysplastic syndrome, with goals to improve quality of life and prolong survival. This review highlights new therapies from the last 18 months.Immunosuppressants, erythropoiesis-stimulating agents in combination with granulocyte colony-stimulating factor or all-trans-retinoic-
Arturo, Loaiza-Bonilla +2 more
openaire +2 more sources
Treatment with Hypomethylating Agents (HMA)
2018In 1993 Silverman and coworkers [1] reported on a phase 2 trial on 43 patients with higher-risk MDS (medullary blast count >10%) using 75 mg/m2 5-Azacytidine (5-Aza) for 7 days every 28 days for 6 cycles. Forty-nine percent of the patients responded, with 12% CR (CR and PR 37%, and 5% improved hematologically without achieving CR or PR), and 51% were ...
Ulrich Germing, Pierre Fenaux
openaire +1 more source